... WhatsApp

Common Blood Pressure Drugs May Help Kidney Cancer Patients Live Longer

You are here >> Home > Latest Updates > Kidney Cancer > Common Blood…

Common Blood Pressure Drugs May Help Kidney Cancer Patients Live Longer

Kidney cancer, also called renal cell carcinoma, can be hard to treat, especially when it spreads. A new study looked at whether a common type of blood pressure medicine, called renin-angiotensin system inhibitors (RAS inhibitors), could help these patients live longer. These medicines include drugs like ACE inhibitors and ARBs, often used to control high blood pressure.

Researchers reviewed data from more than 22,000 kidney cancer patients across 12 studies. They compared people who took RAS inhibitors with those who did not. The results showed that patients using these medicines lived longer and their cancer progressed more slowly.

The benefit was even stronger in patients with advanced or metastatic cancer. In these cases, people taking RAS inhibitors had a better chance of surviving and a slower return of cancer growth. The drugs also seemed to work well when used with newer cancer treatments, such as targeted therapy or immunotherapy.

These findings suggest that RAS inhibitors might do more than control blood pressure—they could also help the body fight cancer. The drugs are already widely available and affordable, making them a promising option for many patients.

Researchers say more clinical trials are needed to confirm these results and to understand how these medicines help. If confirmed, this could give doctors an easy way to improve survival for people living with kidney cancer.

Rate this post

Exclusive Health Tips and Updates

dr swati shah - uro & gynec cancer surgeon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.